The compound you've described, **1-[2-(4-methylphenyl)ethyl]-N-[3-(4-methyl-1-piperazinyl)propyl]-5-oxo-3-pyrrolidinecarboxamide**, is a complex organic molecule with a specific structure. It's important to note that while this name accurately describes the compound's chemical composition, it's not commonly used in research publications.
To understand its significance, it's helpful to break down its structure and identify potential functional groups:
* **1-[2-(4-methylphenyl)ethyl]:** This part indicates a **4-methylphenyl** (a toluene) group attached to an ethyl chain, which is further attached to the main molecule.
* **N-[3-(4-methyl-1-piperazinyl)propyl]:** This indicates a **4-methyl-1-piperazinyl** group attached to a propyl chain, which is then attached to the nitrogen atom (N) of the amide functional group.
* **5-oxo-3-pyrrolidinecarboxamide:** This is the core structure of the molecule. **Pyrrolidine** is a five-membered ring containing a nitrogen atom. **5-oxo** signifies a carbonyl group (C=O) at the 5th position of the ring. **3-carboxamide** indicates an amide group attached at the 3rd position of the ring.
**Why is it important for research?**
The significance of this compound would depend on the specific research context. Without additional information, it's difficult to say definitively. However, based on its structural features, here are some potential areas of interest:
* **Pharmacology:** The presence of the piperazine ring and the amide group suggests potential activity as a drug. Piperazine derivatives are known for their activity on the central nervous system, and amides are often incorporated into drug molecules.
* **Biochemistry:** This compound could be used as a probe to study specific protein-protein interactions or enzyme activity.
* **Materials Science:** The combination of aromatic rings and a nitrogen-containing heterocycle could contribute to interesting properties like fluorescence or conductivity.
**To determine the exact research importance, you would need more information, such as:**
* **The research area:** Is it related to drug discovery, material science, or another field?
* **The specific study:** What is the research question being addressed?
* **The role of the compound:** Is it a potential drug candidate, a probe, or a material building block?
By providing these details, you can get a more accurate understanding of why this specific compound is important for the research.
ID Source | ID |
---|---|
PubMed CID | 5309698 |
CHEMBL ID | 1520515 |
CHEBI ID | 117138 |
Synonym |
---|
EU-0097955 |
smr000097084 |
MLS000120167 |
CHEBI:117138 |
AKOS002133261 |
1-[2-(4-methylphenyl)ethyl]-n-[3-(4-methylpiperazin-1-yl)propyl]-5-oxopyrrolidine-3-carboxamide |
MLS002589078 |
HMS2253O06 |
AKOS021642866 |
CHEMBL1520515 |
1-[2-(4-methylphenyl)ethyl]-n-[3-(4-methyl-1-piperazinyl)propyl]-5-oxo-3-pyrrolidinecarboxamide |
Q27203766 |
sr-01000095192 |
SR-01000095192-1 |
Class | Description |
---|---|
pyrrolidinecarboxamide | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.0119 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 2 (28.57) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |